Philips prices EU green bond for EUR 650M

August 24, 2026

Amsterdam, the Netherlands –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 650 million fixed rate notes due 2034 (the “Notes”) under its European Medium Term Note (EMTN) program. The Notes are the healthcare industry’s first EU Green Bond under the new European Green Bond Standard.

This issuance is not expected to result into an increase of Net Debt. Gross Debt will be temporarily increased until repayment of the 2027 bond maturity in May 2027.

The issue price for the Notes due 2034 is 99.655% with a Coupon of 4.0%, resulting in a yield of 4.055%. The 7.8 year tranche was oversubscribed by 2.7 times.

An amount equivalent to the gross proceeds will be used to finance taxonomy-aligned economic activities as referred to in Philips European Green Bond Factsheet, supporting Philips in delivering on its 2030 Impact Ambition.

Settlement and issue of the Notes is scheduled for August 28, 2026. Application has been made for the Notes to be listed on the Official List of the Luxembourg Stock Exchange and to be traded on the regulated market of the Luxembourg Stock Exchange.
 
Philips is committed to maintaining a strong investment grade credit rating. Currently, the company has a BBB+ rating by Standard & Poor’s (stable outlook), a Baa1 rating by Moody’s (stable outlook) and a BBB+ rating by Fitch (stable outlook). 

THIS PRESS RELEASE IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ‘SECURITIES ACT‘), AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT. THERE IS NO INTENTION TO REGISTER ANY SECURITIES REFERRED TO HEREIN IN THE UNITED STATES OR TO CONDUCT A PUBLIC OFFERING OF SECURITIES IN THE UNITED STATES.

PROHIBITION OF SALES TO EEA RETAIL INVESTORS – The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (the “EEA”). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, “MiFID II”); or (ii) a customer within the meaning of Directive (EU) 2016/97, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended, the “PRIIPs Regulation”) for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.

PROHIBITION OF SALES TO UK RETAIL INVESTORS – The Notes are not intended to be offered, sold, distributed or otherwise made available to and should not be offered, sold, distributed or otherwise  made available to any retail investor in the United Kingdom (the “UK”). For these purposes, a retail investor means a person who is not a professional client as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended, the “EUWA”). Consequently no disclosure document required by the FCA Product Disclosure Sourcebook (“DISC”) for offering, selling or distributing the Notes or otherwise making them available to retail investors in the UK has been prepared and therefore offering, selling or distributing the Notes or otherwise making them available to any retail investor in the UK may be unlawful under DISC and the Consumer Composite Investments (Designated Activities) Regulations 2024.

In the UK, this press release is being distributed to, and is directed at, only (a) persons who have professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”); or (b) high net worth companies, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The Notes are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Notes will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this press release or any of its contents.

Relevant stabilisation regulations including FCA/ICMA apply.

MiFID II and UK MiFIR professionals/ECPs-only

Manufacturer target market (MiFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels).

For further information, please contact:

Michael Fuchs
Philips Global External Relations
Tel.: +31 6 1486 9261
E-mail: [email protected]

Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: [email protected]

About Royal Philips


Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements

This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.



AutoZone to Release Fourth Quarter Fiscal 2026 Earnings September 22, 2026

MEMPHIS, Tenn., Aug. 24, 2026 (GLOBE NEWSWIRE) —  AutoZone, Inc. (NYSE: AZO), a leading retailer and distributor of automotive replacement parts and accessories in the Americas, will release results for its fourth quarter ended Saturday, August 29, 2026, before market open on Tuesday, September 22, 2026. Additionally, the Company will host a one-hour conference call on Tuesday, September 22, 2026, beginning at 10:00 a.m. (ET), to discuss the results of the quarter. This call is being webcast and can be accessed, along with supporting slides, at AutoZone’s website at www.autozone.com and by clicking on Investor Relations. Investors may also listen to the call by dialing (888) 506-0062, passcode AUTOZONE. In addition, a telephone replay will be available by dialing (877) 481-4010, replay passcode 54424 through Tuesday, October 20, 2026.

About AutoZone (NYSE: AZO)
As of May 26, 2026, AutoZone had 6,766 stores in the U.S., 933 in Mexico and 157 in Brazil, for a total store count of 7,856.

AutoZone is a leading retailer and distributor of automotive replacement parts and accessories in the Americas. Each store carries an extensive product line for cars, sport utility vehicles, vans and light duty trucks, including new and remanufactured automotive hard parts, maintenance items, accessories, and non-automotive products. The majority of stores have a Commercial sales program that provides prompt delivery of parts and other products and Commercial credit to local, regional and national repair garages, dealers, service stations, fleet owners and other accounts. AutoZone also sells automotive hard parts, maintenance items, accessories and non-automotive products through www.AutoZone.com, and our Commercial customers can make purchases through www.AutoZonePro.com. Additionally, we sell the ALLDATA brand of automotive diagnostic, repair, collision and shop management software through www.ALLDATA.com. We also provide product information on our Duralast-branded products through www.DuralastParts.com. AutoZone does not derive revenue from automotive repair or installation services.

Contact Information:

Financial: Brian Campbell at (901) 495-7005, [email protected]
Media: Jennifer Hughes at (901) 495-6022, [email protected]



Fifth Third Bancorp to Participate in the Barclays Global Financial Services Conference

Fifth Third Bancorp to Participate in the Barclays Global Financial Services Conference

CINCINNATI–(BUSINESS WIRE)–
Fifth Third Bancorp (NYSE: FITB) will participate in the Barclays Global Financial Services Conference on September 15, 2026, at approximately 7:30 AM ET. Bryan Preston, executive vice president and chief financial officer, and Jamie Leonard, executive vice president and chief operating officer, will represent the Company.

Audio webcast and any presentation slides may be viewed live and for approximately 14 days after the conference through the Investor Relations section of www.53.com. Additionally, any slides used in the presentation will be made available in a printer-friendly format on the Company’s website.

About Fifth Third

Fifth Third is a bank that’s as long on innovation as it is on history. Since 1858, we’ve been helping individuals, families, businesses and communities grow through smart financial services that improve lives. Our list of firsts is extensive, and it’s one that continues to expand as we explore the intersection of tech-driven innovation, dedicated people and focused community impact. Fifth Third is one of the few U.S.-based banks to have been named among Ethisphere’s World’s Most Ethical Companies® for several years. With a commitment to taking care of our customers, employees, communities and shareholders, our goal is to be the one bank people most value and trust.

Fifth Third Bank, National Association is a federally chartered institution. Fifth Third Bancorp is the indirect parent company of Fifth Third Bank, and its common stock is traded on the New York Stock Exchange under the symbol “FITB.” Investor information and press releases can be viewed at www.53.com. Deposit and credit products provided by Fifth Third Bank, National Association. Member FDIC.

Category: Conferences

Matt Curoe (Investor Relations)

[email protected] | 513-534-2345

Jennifer Hendricks Sullivan (Media Relations)

[email protected] | 614-744-7693

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Banking Other Professional Services Professional Services Finance

MEDIA:

Logo
Logo

WeShop First Half 2026 Financial Results Available on its Website

NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) — WeShop Holdings Limited (NASDAQ: WSHP) (“WeShop” or the “Company”) reported first half 2026 financial results today through an earnings release posted on the Company’s Investor Relations website at investors.we.shop. The Company’s financials as of and for six months ended June 30, 2026 and a discussion thereof will also be furnished with the U.S. Securities and Exchange Commission (the “SEC”) on a Form 6-K which is available at sec.gov.

About WeShop

WeShop Holdings Limited (NASDAQ: WSHP) is a pioneering social-commerce platform transforming retail through community ownership. Designed to merge shopping, sharing, and investing, WeShop rewards users with equity for their engagement through its proprietary ShareBack™ program, turning everyday purchases and referring friends who shop through the platform into real ownership. With partnerships spanning hundreds of top retailers and over a billion products, WeShop empowers users to build long-term wealth while discovering and sharing what they love. By combining e-commerce, social interaction, and user ownership, WeShop is leading a global retail revolution—where everyone can earn ownership in the company.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties, including the ability for the WeShop community to earn ownership in WeShop. These forward-looking statements are based on current expectations and WeShop assumes no obligation to update this information. In addition, the events described in these forward-looking statements may not actually arise or may occur in a different manner than anticipated as a result of various factors, including market conditions, as well as other factors described from time to time in WeShop’s filings with the SEC, including its Annual Report on Form 20-F filed with the SEC on April 30, 2026 and its Report on Form 6-K filed with the SEC on August 24, 2026 and which is furnishing with the SEC Weshop’s financial results as of and for the six months ended June 30, 2026. The Company’s filings with the SEC are available at www.sec.gov.

Press:

[email protected]




Corporate:

[email protected]


Commercial:

[email protected]


IR:

[email protected]



Real REMAX Group Announces $450 Million Share Repurchase Authorization

Real REMAX Group Announces $450 Million Share Repurchase Authorization

MIAMI–(BUSINESS WIRE)–
Real REMAX Group Inc. (NASDAQ: REAX) (“Real REMAX Group” or the “Company”), a leading technology-enabled global real estate platform, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to the lesser of $450 million in value, or 25 million in shares of its common stock.

“This authorization reflects our Board’s confidence in Real REMAX Group’s long-term strategy and our commitment to balanced capital allocation,” said Tamir Poleg, Chairman and Chief Executive Officer of Real REMAX Group. “We remain focused on disciplined investment in innovation, supporting our agents, and driving long-term value for all stakeholders – including deleveraging and share repurchases.”

The timing and total amount of stock repurchases, if any, will depend upon market conditions and may be made from time to time in open market purchases, through privately negotiated transactions or otherwise. This program has no termination date. The program may be modified, suspended or discontinued at any time and does not obligate the Company to acquire any amount of common shares.

About Real REMAX Group Inc.

Real REMAX Group Inc. (NASDAQ: REAX) is a leading technology-enabled global real estate platform spanning brokerage, franchising and ancillary services. The fast-growing company combines these essential real estate services with powerful technology to deliver a seamless end-to-end consumer experience, guided by trusted real estate professionals. With 180,000+ agents, more than 100,000 of whom are based in the U.S. and Canada, and a presence in over 120 countries and territories, Real REMAX Group supports agents and broker/owners to power their own forward-thinking businesses. Additional information can be found on its website at www.realremaxgroup.com.

Forward-Looking Statements

Some of the statements in this press release are “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the stock repurchase authorization. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan”, “potential”, “project”, and similar expressions or future or conditional verbs such as “could”, “may”, “should”, “will” and “would”. Such forward-looking statements include, but are not limited to, statements regarding Real REMAX Group leadership’s confidence in the execution of its strategy; statements regarding the anticipated benefits of the recently completed business combination (the “business combination”) by and between The Real Brokerage Inc. (“legacy Real”) and RE/MAX Holdings, Inc. (“legacy REMAX”); the anticipated impact of the business combination on Real REMAX Group’s business and financial and operating results, including its expected leverage and the amount and timing of synergies from the business combination; and the anticipated amount, manner and timing of execution of the share repurchase program. These statements inherently involve numerous risks, uncertainties, and assumptions that could cause actual results to differ materially from those projected in these statements, including statements about the anticipated benefits of the business combination. Where, in any forward-looking statement, Real REMAX Group expresses an expectation or belief as to future results or events, it is based on Real REMAX Group’s current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, Real REMAX Group cannot give any assurance that any such expectation or belief as to future results will be achieved or accomplished. Significant risk factors that may cause such a difference include, but are not limited to, risks related to disruption from the business combination, including disruption of management time from current plans and ongoing business operations due to the business combination and matters relating to integrating the businesses of legacy Real and legacy REMAX; the risk that the business combination could have an adverse effect on Real REMAX Group’s ability to retain agents, franchisees and personnel or that there could be potential adverse reactions or changes to business relationships resulting from the business combination; unexpected costs, charges or expenses resulting from the business combination; potential litigation relating to the business combination and the effects of any outcomes related thereto; the ability of Real REMAX Group to achieve the synergies and other anticipated benefits expected from the business combination or such synergies and other anticipated benefits taking longer to realize than anticipated; the ability of Real REMAX Group to achieve the expected leverage or such leverage taking longer to realize than anticipated; anticipated tax treatment, unforeseen liabilities, future capital expenditures, economic performance, future prospects and business and management strategies for the management, expansion and growth of the Company’s operations; slowdowns in real estate markets, economic and industry downturns, Real REMAX Group’s ability to attract new agents and retain current agents, Real REMAX Group’s inability to successfully launch new products and features; Real REMAX Group’s inability to scale while improving operating leverage, or inability to successfully execute its strategies, including its strategy related to HeyLeo; possible unfavorable results in legal proceedings; changes in laws, regulations or the regulatory environment affecting our business; disruption to our technology or cybersecurity incidents; and other risk factors detailed from time to time in our reports filed with the SEC, as well as in legacy Real’s and legacy REMAX’s reports filed with the SEC, including legacy Real’s annual report on Form 40-F, reports on Form 6-K and other documents filed with the SEC, and legacy REMAX’s annual report on Form 10-K, quarterly reports on Form 10-Q, reports on Form 8-K and other documents filed with the SEC, copies of which are available at www.sec.gov, and legacy Real’s reports filed with Canadian securities regulators, including legacy Real’s audited annual financial statements and annual management’s discussion and analysis for the financial year ended December 31, 2025, Annual Information Form dated March 4, 2026 and quarterly financial statements and quarterly management’s discussion and analysis for the period ended June 30, 2026, copies of which are available under legacy Real’s SEDAR+ profile at www.sedarplus.ca.

Real REMAX Group does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Neither future distribution of this press release nor the continued availability of this press release in archive form on Real REMAX Group’s website should be deemed to constitute an update or re-affirmation of these statements as of any future date.

Investor Relations

Loren Irwin

Director, Investor Relations and Financial Reporting

[email protected]

908.280.2515

Media Relations

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Professional Services Technology Residential Building & Real Estate Commercial Building & Real Estate Software Construction & Property Fintech

MEDIA:

Logo
Logo

Orangekloud Technology Inc. Enters into Definitive Agreement to Acquire Orbis Technology Limited, Operator of VeVe

Company to be renamed VeVe Inc. and trade on Nasdaq under ticker symbol “VEVE” upon closing; transaction contemplates concurrent private placement of $30 million to $100 million

SINGAPORE, Aug. 24, 2026 (GLOBE NEWSWIRE) — Orangekloud Technology Inc. (Nasdaq: ORKT) (“Orangekloud” or “the Company”), a Singapore-based technology company offering the eMOBIQ® No-Code platform for the development of mobile applications and SaaS subscription-based ISV Solutions, today announced that it has entered into a definitive Agreement and Plan of Exchange of Securities (the “Exchange Agreement”) with Orbis Technology Limited (“Orbis”), a New Zealand company and the operator of VeVe Inc., the largest mobile-first digital collectibles platform.

Upon closing of the transaction, Orbis will become a subsidiary of the Company, which will be renamed VeVe Inc. and trade on Nasdaq under ticker symbol “VEVE”.

The Exchange Agreement follows the non-binding Letter of Intent announced on February 11, 2026, and represents the definitive agreement contemplated thereunder.

Orbis is a global digital intellectual property (IP) infrastructure company that enables leading brands to issue, authenticate, and monetize licensed digital assets at scale. Orbis operates across IP ingestion, rights management, marketplace infrastructure, and secondary-market monetization, providing an end-to-end platform for digital IP lifecycle management. VeVe is Orbis’s flagship consumer-facing brand and marketplace, serving as a distribution and demand engine for the Group’s underlying IP infrastructure.

Key Transaction Terms

  • Exchange consideration and exchange ratio. Up to 3,967,705 Orbis capital shares, representing 100% of the Orbis capital shares outstanding immediately prior to closing, may be exchanged for the issuance of up to 600,000,000 ordinary shares of the Company, at a deemed value of $1.00 per share, subject to adjustment for the exercise of certain Orbis warrants. At the effective time, each Orbis ordinary share held by an Orbis shareholder that is a party to the Exchange Agreement will be exchanged for 37.8048 Class A ordinary shares and 113.4144 Class B ordinary shares of the Company, up to approximately 150,017,021 Class A ordinary shares and approximately 449,982,979 Class B ordinary shares in the aggregate.
  • Warrants. As of the date of the Exchange Agreement, 101,736 warrants to acquire Orbis capital shares were outstanding. Orbis warrants exercised prior to the effective time will be exchanged on the same pro rata basis as other Orbis capital shares; any warrants that remain outstanding at the effective time may either remain outstanding and unchanged or be replaced with warrants exercisable for Class A and Class B ordinary shares of the Company in accordance with the conversion provisions of the Exchange Agreement. Separately, in connection with the closing, the Company intends to issue to its advisor 90,927,946 warrants, each exercisable for one Class A ordinary share at an exercise price of $1.00 per share. Mutual agreement on the form of such warrant is a condition to closing.
  • Equity incentive and management awards. The Exchange Agreement permits the Company to grant awards under its 2025 Equity Incentive Plan covering up to 875,965 shares, and to grant performance- and service-based restricted stock units to each of Goh Kian Hwa and Lung Lay Hua with an aggregate value of up to $3 million each, subject to the conditions set forth in the Exchange Agreement.
  • Advisory fees. The Company may issue up to $3.5 million of restricted shares as an advisory success fee, contingent upon closing. The Exchange Agreement also provides for the payment of a finder’s fee in connection with certain operating expense financing, not to exceed 6% of the funds raised.
  • Shareholder support. Holders of more than 75% of the outstanding capital stock of Orbis have executed the Exchange Agreement. The Company anticipates that this percentage will increase to at least 93% pursuant to drag-along rights contained in an agreement among Orbis shareholders.
  • Concurrent financing. At or prior to closing, the Company is required to complete a private placement of Class A ordinary shares for aggregate gross proceeds of a minimum of $30 million and a maximum of $100 million. Of the proceeds, $3 million is to be provided at closing to a wholly owned operating subsidiary of the Company for ordinary-course operations related to its current mobile applications and SaaS solutions.
  • Orbis deposit. Orbis intends to provide the Company with $1 million in cash within 60 days of the date of the Exchange Agreement. The payment is non-refundable, subject to limited exceptions, and is restricted to use for the Company’s operations and ordinary-course business purposes.
  • Board and management. Following the effective time, the board of directors will consist of seven directors: Goh Kian Hwa and Lung Lay Hua, each a current director of the Company; four nominees designated by Orbis; and one nominee designated by the Company’s advisor. The post-closing board is required to satisfy Nasdaq independence requirements. Senior executive officer positions of the post-closing company will be held by individuals designated by Orbis.
  • Share structure. Holders of the Company’s existing Class B ordinary shares have delivered irrevocable instructions to convert all such shares into Class A ordinary shares effective upon, and conditioned on, the closing, and have agreed to vote in favor of the transaction. Holders of Orbis equity interests have entered into lock-up agreements covering the twelve-month period following the closing, subject to customary permitted transfers.
  • Nasdaq listing. The Company will use its reasonable best efforts to cause the Class A ordinary shares issued in the transaction to be approved for listing on the Nasdaq Stock Market at or after the effective time.
  • Additional financings. In addition to the concurrent private placement described above, the Exchange Agreement permits the Company to conduct an operating expense financing of up to $6 million, subject to the pricing, use-of-proceeds and 20% ownership limitations set forth in the Exchange Agreement.

“Signing this definitive agreement is a significant milestone for Orangekloud and for our shareholders,” said Goh Kian Hwa, Chief Executive Officer of Orangekloud Technology Inc. “Since announcing our letter of intent in February, both teams have worked diligently to reach terms that we believe position the combined business for its next stage of growth. Orbis has built genuine infrastructure for licensed digital IP, and VeVe has established a marketplace and audience at meaningful scale. We look forward to working toward the satisfaction of the closing conditions, including shareholder approval, and to keeping our shareholders informed as the process advances.”

“This agreement is an important step for Orbis and for VeVe,” said David Yu, Chief Executive Officer of Orbis. “Collectibles are one of the fastest-growing categories in consumer culture overall, and VeVe has established itself as a clear market leader in digital collectibles. This transaction supports our long-term plans for the platform and for the brands we work with, and we look forward to working with the Orangekloud team toward closing.”

Completion of the transaction is subject to the satisfaction or waiver of customary closing conditions, including final approval of the Company’s board of directors subject to receipt of a satisfactory independent fairness opinion; completion of financial, tax, and legal due diligence; confirmation of committed financing; approval by the Company’s shareholders at an extraordinary general meeting; approval for listing on Nasdaq of the Class A ordinary shares to be issued in the transaction; receipt of any required consent or non-objection from the New Zealand Overseas Investment Office; and the absence of any legal restraint preventing the transaction. The Exchange Agreement may be terminated by either party if the closing has not occurred by December 31, 2026, subject to extension in specified circumstances. There can be no assurance that the transaction will be completed on the terms described, on the anticipated timeline, or at all.

About Orangekloud Technology Inc.

Orangekloud Technology Inc. (Nasdaq: ORKT) is a Singapore-based technology company which offers the eMOBIQ® No-Code platform to develop mobile applications specially designed for Small and Medium Enterprises (SMEs) and corporations. A suite of eMOBIQ® mobile applications designed to digitalize and streamline operations in warehousing, sales ordering, delivery, manufacturing, and other key areas. The industry sectors focused on include Food Services & Manufacturing, Precision Engineering, Construction, etc.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the U.S. federal securities laws with respect to the parties and the transaction. The Company’s and/or Orbis’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. No representations or warranties, express or implied are given in, or in respect of, this press release. When this press release uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.

These forward-looking statements and factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Exchange Agreement with respect to the transaction; (2) the outcome of any legal proceedings that may be instituted against the parties following the announcement of the transaction and definitive agreements with respect thereto; (3) the inability to complete the transaction, including due to failure to obtain approval of the shareholders of the Company or Orbis or other conditions to closing; (4) the inability to obtain or maintain the listing of the Company’s shares on Nasdaq or another national securities exchange following the transaction; (5) the ability of the Company to remain current with its SEC filings; (6) the risk that the transaction disrupts current plans and operations as a result of the announcement and consummation of the transaction; (7) the ability to recognize the anticipated benefits of the transaction, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (8) costs related to the transaction; (9) changes in applicable laws or regulations; (10) the inability of Orbis to implement business plans, forecasts, and other expectations after the completion of the transaction; (11) the risk that the concurrent private placement contemplated by the Exchange Agreement, or additional capital needed following the transaction to support the combined company’s business or operations, may not be raised on favorable terms or at all; and (12) other risks and uncertainties included in documents filed or furnished with the SEC by the Company.

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s annual report on Form 20-F and other documents filed or furnished by the Company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. There may be additional risks that neither the Company nor Orbis presently knows, or that the Company and/or Orbis currently believe are immaterial, that could cause actual results to differ from those contained in the forward-looking statements. For these reasons, among others, investors and other interested persons are cautioned not to place undue reliance upon any forward-looking statements in this press release. Neither the Company nor Orbis undertakes any obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this press release, except as required by applicable law.

NO OFFER OR SOLICITATION

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the transaction and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.

Orangekloud Technology Inc. IR Contact:

Steven Chu, COO and IR Officer
70 Bendemeer Road #04-04 Luzerne
Singapore 339940
(+65) 6317 2050
Email: [email protected]

Investor Relations Inquiries:

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: [email protected]



Rackspace Technology, Inc. Securities Fraud Class Action Lawsuit Filed; September 28, 2026, Lead Plaintiff Deadline

Did you buy RXT securities between May 7, 2026 and July 8, 2026
?

Affected RXT Investor Summary

  • Who: Rackspace Technology, Inc. (NASDAQ: RXT)
  • What: Securities fraud class action lawsuit filed
  • Class Period: May 7, 2026 through July 8, 2026
  • Deadline to Seek Lead Plaintiff Status: September 28, 2026
  • Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s enterprise AI efforts.   
  • Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options

RADNOR, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) — Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Rackspace Technology, Inc. (Rackspace) (NASDAQ: RXT) on behalf of those who purchased or acquired Rackspace securities between May 7, 2026 and July 8, 2026, inclusive. The lawsuit is filed in the United States District Court for the Southern District of New York and is captioned Morgan-Reed v. Rackspace Technology, Inc., No. 1:26-cv-06491 (S.D.N.Y.). Investors have until September 28, 2026, to file for lead plaintiff status.  


CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:


If you purchased or acquired Rackspace securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/rxt-rackspace-technology-inc-class-action-lawsuit?utm_source=Globe&utm_medium=pressrelease&utm_campaign=rxt&mktm=PR

You can also contact attorney

Jonathan Naji, Esq.

by calling (484) 270-1453 or by email at

[email protected]

. There is no cost or obligation to speak with an attorney.


To view the Rackspace video on YouTube, click here:



https://youtu.be/SGYNCxPHZ2c?si=vzxUeEhLFRsDoqkR


RACKSPACE TECHNOLOGY, INC.


CLASS ACTION LAWSUIT – COMPLAINT ALLEGATION SUMMARY:


The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Rackspace’s enterprise AI efforts would require the company to significantly re-prioritize its capacity and capital away from the profitable Private Cloud segment; (2) Rackspace’s Public Cloud revenue was declining as customers contracted directly with hyperscale cloud platforms; (3) as a result, Rackspace was likely to significantly reduce a material portion of its Public Cloud infrastructure resale business; (4) consequently, Rackspace’s fiscal year 2026 revenue would be significantly impacted; and (5) as a result of the foregoing, Defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Why did Rackspace’s Stock Drop?

On July 9, 2026, before the market opened, Rackspace published its second quarter 2026 financial results and disclosed “a strategic and financial update on its transition to becoming the operator of the full enterprise AI stack.” Specifically, Rackspace revealed that its AI investments would require a significant re-prioritization of resources and, as a result, reduced its full year 2026 revenue guidance by $150 million. Rackspace also cut its full year 2026 Private Cloud revenue outlook by $25 million and explained that “[l]ower near-term margins reflect upfront growth investment and restructuring, ahead of AI revenue ramping.”

On this news, Rackspace’s stock price fell $2.21 per share, or 33.6%, to close at $4.37 per share on July 9, 2026.


WHAT RACKSPACE TECHNOLOGY, INC. INVESTORS CAN DO NOW:

  1. File to be lead plaintiff by September 28, 2026.
  2. Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.
  3. Retain counsel of choice or take no action.


THE LEAD PLAINTIFF PROCESS FOR RACKSPACE TECHNOLOGY, INC. INVESTORS:


Rackspace investors may, no later than September 28, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.


Kessler Topaz Meltzer & Check, LLP
encourages Rackspace investors to contact the firm for more information.


ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. The complaint in this matter was not filed by KTMC.

CONTACT:

Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]
        
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.



Hub Group Receives Expected Deficiency Notice from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

OAK BROOK, Ill., Aug. 24, 2026 (GLOBE NEWSWIRE) — Hub Group, Inc. (Nasdaq: HUBG) today announced that on August 20, 2026, as expected, it received a notice indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of its failure to timely file its Form 10-Q for the quarter ended June 30, 2026 (the “Form 10-Q”). The Listing Rule requires Nasdaq-listed companies to timely file all required periodic reports with the SEC.

The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq.

About Hub Group

Hub Group offers comprehensive transportation and logistics management solutions. Keeping our customers’ needs in focus, Hub Group designs, continually optimizes, and applies industry-leading technology to our customers’ supply chains for better service, greater efficiency, and total visibility. As an award-winning, publicly traded company (Nasdaq: HUBG), our approximately 6,000 employees and drivers across the globe are always in pursuit of “The Way Ahead” – a commitment to service, integrity and innovation. For more information, visit hubgroup.com.

CONTACT: Garrett Holland, [email protected]



Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

  • Dual-action eye drop targeting both evaporative and inflammatory dry eye disease moving to Phase 3
  • Positive Phase 1b results for ocular surface pain candidate validate TRPV1 antagonist approach and strengthen confidence in ongoing Phase 2 study
  • Combined potential peak sales exceeding $2 billion assuming successful development and commercialization1

VAUGHAN, Ontario–(BUSINESS WIRE)–
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results.

“Helping people see better to live better starts with tackling the challenges patients still face every day,” said Bausch + Lomb CEO Brent Saunders. “These results support our approach to developing differentiated therapies that have the potential to address significant unmet needs and change the standard of care in eye health.”

Dry Eye Disease Dual-Action Eye Drop: Phase 2 Results Support Advancement to Phase 3 with Day 15 Primary Endpoint

Dry eye disease is a complex, multifactorial condition affecting millions of people worldwide. While existing prescription therapies can effectively address individual causes of dry eye disease, no approved treatment addresses both the inflammatory and evaporative drivers of the disease in a single therapy. Patients often continue to experience persistent symptoms despite treatment, highlighting the need for new approaches that more comprehensively address the condition.

Bausch + Lomb has developed a first-in-class dual-action eye drop that combines 5% lifitegrast (the active ingredient in XIIDRA®) and perfluorohexyloctane (PFHO; the active ingredient in MIEBO®) into a single twice-daily treatment designed to address both ocular surface inflammation and tear evaporation – two of the primary underlying causes of dry eye disease.

Study Design and Results

A four-week, randomized, double-masked, parallel-group, active-controlled Phase 2 study enrolled 443 patients with dry eye disease (age 18 and older) across six arms: the dual-action eye drop, lifitegrast alone, PFHO alone and three vehicle masking controls. This was the first clinical study of the combination, and Day 29 was selected as the primary endpoint timepoint in the absence of prior human data on the timing of the combined treatment effect.

The study did not meet its primary endpoint of superiority over lifitegrast alone in reducing total corneal fluorescein staining (tCFS) from baseline at Day 29, although results numerically favored the dual-action eye drop (p=0.196). A pre-specified secondary analysis at Day 15 – a timepoint accepted by the Food and Drug Administration as a registrational primary endpoint for tCFS – showed a significant reduction in mean change from baseline tCFS for the dual-action eye drop versus lifitegrast alone (p=0.0007). At Day 15, 41.6% of patients treated with the dual-action eye drop achieved a ≥3-unit improvement in tCFS, compared with 18.8% of patients treated with lifitegrast alone and 31.6% treated with PFHO alone.

The safety profile in all three treatment groups was consistent with the established profiles of XIIDRA and MIEBO, with no new safety signals identified.

Path to Phase 3

The data provide a clear path forward, and Bausch + Lomb will advance the dual-action eye drop into Phase 3 development with a primary endpoint at Day 15.

Notably, the dual-action eye drop achieved these results with more than 50% less lifitegrast volume than XIIDRA and half the dosing frequency of MIEBO. The company believes this profile – a rapid treatment effect at a lower drug load and simplified dosing regimen – supports the design of Phase 3 studies to demonstrate superiority to both individual therapies. Details of the Phase 3 program will be shared in the coming months.

“This was the first time this combination has been studied in humans, and it did exactly what a Phase 2 should do: demonstrated a rapid, robust treatment effect and told us precisely when to measure it,” said Yehia Hashad, MD, executive vice president, R&D and chief medical officer, Bausch + Lomb. “With a pre-specified result of this strength at a registrationally accepted timepoint achieved with less drug than the individual therapies, and the ability to increase the dose based on an acceptable safety profile, we’re advancing to Phase 3 with a clear design and high conviction.”

Ocular Surface Pain Program: Positive Phase 1b Results Confirm TRPV1 Mechanism in Humans and Support Continued Development of BL1332; Phase 2 Results Expected Within Next Few Months

Ocular surface pain is the leading reason patients seek care from eye care professionals and can affect individuals with dry eye disease, corneal disease and post-surgical complications. Despite its prevalence and impact on quality of life, there are currently no approved therapies specifically designed to target the underlying neurosensory pathways responsible for ocular surface pain, leaving many patients with limited treatment options.

Bausch + Lomb has developed BL1332, a first-in-class topical TRPV1 antagonist designed to target a key receptor involved in ocular pain signaling. Unlike therapies that primarily address associated signs or symptoms, BL1332 is intended to directly modulate the biological pathways that drive ocular surface pain. The investigational therapy is being evaluated as a potential treatment for multiple forms of ocular surface pain, including post-surgical, acute and chronic conditions. Based on its mechanism and clinical experience to date, the company believes BL1332 could support development across multiple ocular surface pain patient populations.

Study Design and Results

A Phase 1b study evaluated BL1332 0.30% ophthalmic solution in a capsaicin-induced ocular pain challenge model in healthy adult participants. The study met its primary endpoint, demonstrating a statistically significant reduction in pain intensity compared with vehicle and providing the first clinical confirmation that TRPV1 blockade can reduce ocular pain in humans beyond acute post-surgical pain. At five seconds following capsaicin challenge, BL1332-treated eyes experienced a 5.5-point reduction in mean pain intensity versus vehicle (p<0.0001). In exploratory analyses, 68.2% of BL1332-treated eyes achieved complete pain resolution compared with 0% of vehicle-treated eyes (p<0.0001), while no BL1332-treated eyes reported severe pain compared with 36.4% of vehicle-treated eyes receiving vehicle (p<0.01). Mean duration of pain following capsaicin challenge was also markedly shorter with BL1332 than with vehicle (1.6 versus 37.8 seconds; p<0.0001). The safety profile was acceptable and consistent with previous clinical experience, with no new safety signals identified.

The company believes these results validate the underlying mechanism of BL1332 and provide a foundation for ongoing studies designed to evaluate the therapy in patients experiencing clinically relevant ocular pain conditions.

Path Forward

Bausch + Lomb is currently evaluating BL1332 in an ongoing Phase 2 study in patients experiencing pain following photorefractive keratectomy surgery, with topline results expected in the coming months. The study is intended to assess the potential of BL1332 in a real-world clinical setting and represents the next step in defining the therapeutic profile of the program.

Beyond post-surgical pain, the company believes BL1332’s mechanism may have potential relevance across multiple ocular surface pain conditions, including pain associated with dry eye disease and other acute and chronic ocular disorders. Future development decisions will be informed by ongoing clinical results and discussions with regulatory authorities.

“These results provide the first clinical evidence that targeting TRPV1 can meaningfully reduce ocular pain in humans that have not just undergone surgery,” stated Hashad. “They also strengthen our confidence in the mechanism as we continue evaluating BL1332 in patients with clinically relevant pain conditions.”

Potential Financial Impact

As shared at Investor Day in November 2025, estimated peak sales for the dual-action dry eye disease therapy are approximately $700 million, assuming successful development and commercialization. Peak sales for BL1332, the ocular surface pain candidate, are estimated at approximately $1.4 billion, assuming successful development and labeling across multiple ocular surface pain conditions.

Both programs are expected to provide a meaningful financial contribution upon approval and commercialization beyond 2028, further supporting Bausch + Lomb’s long-term growth outlook. The company remains on track to achieve the three-year targets outlined at Investor Day.

Call with R&D Leadership

Today at 5:30 p.m. ET, Brent Saunders will be joined by Dr. Yehia Hashad and Dr. Mayssa Attar for a presentation of the results followed by a Q&A session. Details:

Date:

Monday, Aug. 24, 2026

Time:

5:30 p.m. ET

Webcast:

https://www.webcaster5.com/Webcast/Page/2883/54475

Participant Event Dial-in:

+1 (888) 506-0062 (North America)

+1 (973) 528-0011 (International)

Participant Access Code:

868187

Replay Dial-in:

+1 (877) 481-4010 (North America)

+1 (919) 882-2331 (International)

Replay Passcode:

54475 (replay available until Sept. 7, 2026)

About Bausch + Lomb

Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

Forward-looking Statements

This news release may contain forward-looking information and statements within the meaning of applicable securities laws (collectively, “forward-looking statements”). Forward-looking statements may generally be identified by the use of the words “anticipates,” “seeks,” “expects,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “potential,” “pending” or “proposed” and variations or similar expressions. Forward-looking statements including the company’s estimates for potential peak sales of its pipeline products and the company’s plans for future development and the timing of same. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

© 2026 Bausch + Lomb.

________________________ 

1 Represents total projected peak sales of both pipeline products, with anticipated peaks staggered based on launch dates.

 

Media Contact:

Caryn Marshall

[email protected]

(908) 493-1381

Investor Contact:

George Gadkowski

[email protected]

(877) 354-3705 (toll free)

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Optical Clinical Trials

MEDIA:

Logo
Logo

Real and RE/MAX Holdings Announce Completion of Business Combination

Real and RE/MAX Holdings Announce Completion of Business Combination

MIAMI–(BUSINESS WIRE)–
Real REMAX Group Inc. (NASDAQ: REAX) (“Real REMAX Group”) announced the successful completion of the previously announced business combination between The Real Brokerage Inc. (“Real”) and RE/MAX Holdings, Inc. (“RE/MAX Holdings”). The combined company is operating under the name Real REMAX Group Inc.

Real’s common shares and RE/MAX Holdings’ class A Common Stock ceased trading on the Nasdaq Global Select Market (the “Nasdaq”) and the New York Stock Exchange, respectively, upon close of trading today. Beginning tomorrow, August 25, 2026, shares of Real REMAX Group’s common stock will start trading on the Nasdaq under the symbol “REAX”.

Under the terms of the Arrangement Agreement and Plan of Merger (the “Merger Agreement”), former Real shareholders received, following a 10 for 1 share consolidation, one share of common stock in Real REMAX Group for each Real common share owned and former RE/MAX Holdings stockholders received, based on elections made by such stockholders which were subject to the proration mechanics described in the Merger Agreement, either (i) 0.515 shares of common stock of Real REMAX Group or (ii) approximately $4.33 in cash and approximately 0.3535 shares of common stock of Real REMAX Group for each share of RE/MAX Holdings’ Class A Common Stock owned.

“This acquisition marks a significant milestone on our journey to build a technology platform that empowers real estate professionals and improves the consumer experience,” said Tamir Poleg, Chairman and Chief Executive Officer of Real REMAX Group. “Bringing together Real’s technology and operating model with REMAX’s global reach and franchise model is a transformational moment for the industry. Together, we are creating a more innovative, more productive and more connected real estate ecosystem that we believe will generate substantial long-term value for agents, franchisees, consumers and shareholders.”

About Real REMAX Group

Real REMAX Group Inc. (NASDAQ: REAX) is a leading technology-enabled global real estate platform spanning brokerage, franchising and ancillary services. The fast-growing company combines these essential real estate services with powerful technology to deliver a seamless end-to-end consumer experience, guided by trusted real estate professionals. With 180,000+ agents, more than 100,000 of whom are based in the U.S. and Canada, and a presence in over 120 countries and territories, Real REMAX Group supports agents and broker/owners to power their own forward-thinking businesses. Additional information can be found on its website at www.realremaxgroup.com.

Advisors

Morgan Stanley served as exclusive financial advisor and Willkie Farr & Gallagher LLP and Gowling WLG (Canada) LLP served as legal counsel to Real. J.P. Morgan served as exclusive financial advisor and Morrison & Foerster LLP and McCarthy Tétrault LLP served as legal counsel to RE/MAX Holdings.

Cautionary Disclosure Regarding Forward-Looking Statements

Some of the statements in this press release are “forward-looking statements” and “forward-looking information” within the meaning of applicable United States and Canadian securities laws, including Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the amount and timing of synergies from the recently completed business combination (the “business combination”) by and between The Real Brokerage Inc. (“legacy Real”) and RE/MAX Holdings, Inc. (“legacy REMAX”). Forward-looking statements/forward-looking information include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan”, “potential”, “project”, and similar expressions or future or conditional verbs such as “could”, “may”, “should”, “will” and “would”. Such forward-looking statements/forward-looking information include, but are not limited to, statements regarding Real REMAX Group leadership’s confidence in the execution of its strategy; statements regarding the anticipated benefits of the business combination; the anticipated impact of the business combination on Real REMAX Group’s business and financial and operating results, including its expected leverage and the amount and timing of synergies from the business combination. These statements inherently involve numerous risks, uncertainties, and assumptions that could cause actual results to differ materially from those projected in these statements, including statements about the anticipated benefits of the business combination. Where, in any forward-looking statement, Real REMAX Group expresses an expectation or belief as to future results or events, it is based on Real REMAX Group’s current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, Real REMAX Group cannot give any assurance that any such expectation or belief as to future results will be achieved or accomplished. Significant risk factors that may cause such a difference include, but are not limited to, risks related to disruption from the business combination, including disruption of management time from current plans and ongoing business operations due to the business combination and matters relating to integrating the businesses of legacy Real and legacy REMAX; the risk that the business combination could have an adverse effect on Real REMAX Group’s ability to retain agents, franchisees and personnel or that there could be potential adverse reactions or changes to business relationships resulting from the business combination; unexpected costs, charges or expenses resulting from the business combination; potential litigation relating to the business combination and the effects of any outcomes related thereto; the ability of Real REMAX Group to achieve the synergies and other anticipated benefits expected from the business combination or such synergies and other anticipated benefits taking longer to realize than anticipated; the ability of Real REMAX Group to achieve the expected leverage or such leverage taking longer to realize than anticipated; anticipated tax treatment, unforeseen liabilities, future capital expenditures, economic performance, future prospects and business and management strategies for the management, expansion and growth of Real REMAX Group’s operations; slowdowns in real estate markets, economic and industry downturns, Real REMAX Group’s ability to attract new agents and retain current agents, Real REMAX Group’s inability to successfully launch new products and features; Real REMAX Group’s inability to scale while improving operating leverage, or inability to successfully execute its strategies, including its strategy related to HeyLeo; possible unfavorable results in legal proceedings; changes in laws, regulations or the regulatory environment affecting our business; disruption to our technology or cybersecurity incidents; and other risk factors detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission (the “SEC”), as well as in legacy Real’s and legacy REMAX’s reports filed with the SEC, including legacy Real’s annual report on Form 40-F, reports on Form 6-K and other documents filed with the SEC, and legacy REMAX’s annual report on Form 10-K, quarterly reports on Form 10-Q, reports on Form 8-K and other documents filed with the SEC, copies of which are available at www.sec.gov, and legacy Real’s reports filed with Canadian securities regulators, including legacy Real’s audited annual financial statements and annual management’s discussion and analysis for the financial year ended December 31, 2025, Annual Information Form dated March 4, 2026 and quarterly financial statements and quarterly management’s discussion and analysis for the period ended June 30, 2026, copies of which are available under legacy Real’s SEDAR+ profile at www.sedarplus.ca.

Real REMAX Group does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Neither future distribution of this press release nor the continued availability of this press release in archive form on Real REMAX Group’s website should be deemed to constitute an update or re-affirmation of these statements as of any future date.

Investor Relations

Loren Irwin

Director, Investor Relations and Financial Reporting

[email protected]

908.280.2515

Media Relations

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Residential Building & Real Estate Commercial Building & Real Estate Other Technology Technology Construction & Property

MEDIA:

Logo
Logo